Xeris Biopharma Holdings, Inc. stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Xeris Biopharma Holdings, Inc. stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Xeris Biopharma Holdings, Inc. do? Business model and key facts
Get the full picture of Xeris Biopharma Holdings, Inc.: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 435
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Stocks related to Xeris Biopharma Holdings, Inc.
Selected based on industry alignment and relative market positioning.
Events and news impacting Xeris Biopharma Holdings, Inc. stock
Earnings, coporate decisions and industry developments that can affect the share price.
Xeris Biopharma Holdings, Inc. fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
